We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $687M Turnover 33.33%
1-Year Est. Return 17.07%
This Fund
S&P 500
This Quarter Est. Return
-3.23%
1 Year Est. Return
+17.07%
3 Year Est. Return
+153.83%
5 Year Est. Return
+59.36%
10 Year Est. Return
+1,174.6%
AUM
$4.84B
AUM Growth
-$282M
Cap. Flow
-$20.2M
Cap. Flow %
-0.42%
Top 10 Hldgs %
88.92%
Holding
82
New
22
Increased
15
Reduced
12
Closed
13
Avg Time Held Equity + Options
1 year
Top 10 Avg Time Held Equity + Options
1 year
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
1.1 years
Top 10 Avg Time Held Equity only
1.5 years
Top 20 Avg Time Held Equity only
1.4 years

Top Sells

Rank Stock Value
1
CELG
Celgene
CELG
+$37.2M
2
MA icon
Mastercard
MA
+$18.9M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$14.2M
4
JPM icon
JPMorgan Chase
JPM
+$12.5M
5
DAL icon
Delta Air Lines
DAL
+$9.7M

Sector Composition

Rank Sector Weight
1 Consumer Staples 55.65%
2 Healthcare 23.71%
3 Miscellaneous 10.68%
4 Consumer Discretionary 8.41%
5 Financials 1.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
BUFF icon
1
DELISTED
Blue Buffalo Pet Products
BUFF
$2.68B 55.4%
114,987,547
– –
2015 Q3
3 quarters
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$681M
$825M 17.04%
57,517,977
– –
2013 Q2
12 quarters
WW icon
3
DELISTED
WW International
WW
$342M 7.07%
29,443,300
– –
2013 Q2
12 quarters
GS icon
4
CALL
Goldman Sachs
GS
$228B
$186M 3.83%
1,250,000
+250,000
+25% +$39M
2015 Q1
5 quarters
BAC icon
5
CALL
Bank of America
BAC
$325B
$66.4M 1.37%
5,000,000
+500,000
+11% +$7.02M
2016 Q1
1 quarter
INCY icon
6
Incyte
INCY
$23.4B
$50M 1.03%
625,000
+25,000
+4% +$1.94M
2014 Q1
9 quarters
REGN icon
7
CALL
Regeneron Pharmaceuticals
REGN
$95.2B
$41.9M 0.87%
120,000
+90,000
+300% +$34.7M
2016 Q1
1 quarter
ALNY icon
8
Alnylam Pharmaceuticals
ALNY
$19.3B
$39.4M 0.81%
710,000
+110,000
+18% +$6.93M
2013 Q4
10 quarters
WMT icon
9
CALL
Walmart
WMT
$1.02T
$36.5M 0.75%
1,500,000
– –
2015 Q1
5 quarters
BIIB icon
10
CALL
Biogen
BIIB
$36.9B
$36.3M 0.75%
150,000
-250,000
-63% -$65.9M
2014 Q1
9 quarters
BABA icon
11
Alibaba
BABA
$202B
$31.8M 0.66%
400,000
+25,000
+7% +$1.96M
2014 Q3
7 quarters
GS icon
12
Goldman Sachs
GS
$228B
$29.7M 0.61%
200,000
– –
2016 Q1
1 quarter
GOOGL icon
13
CALL
Alphabet (Google) Class A
GOOGL
$3.26T
$28.1M 0.58%
+800,000
New +$29.4M
2016 Q2
0 quarters
BMRN icon
14
BioMarin Pharmaceuticals
BMRN
$11.7B
$27.2M 0.56%
350,000
-50,000
-13% -$4.25M
2013 Q2
12 quarters
NKTR icon
15
Nektar Therapeutics
NKTR
$1.03B
$19.9M 0.41%
93,333
-40,000
-30% -$8.94M
2013 Q2
12 quarters
MET icon
16
CALL
MetLife
MET
$60.1B
$19.9M 0.41%
500,000
-250,000
-33% -$10.9M
2014 Q1
9 quarters
CELG
17
CALL
DELISTED
Celgene
CELG
$19.7M 0.41%
200,000
-100,000
-33% -$10.3M
2015 Q1
5 quarters
BLUE icon
18
DELISTED
bluebird bio
BLUE
$19.5M 0.4%
22,500
-2,500
-10% -$2.19M
2013 Q3
11 quarters
REGN icon
19
Regeneron Pharmaceuticals
REGN
$95.2B
$17.5M 0.36%
+50,000
New +$19.3M
2016 Q2
0 quarters
APTV icon
20
Aptiv
APTV
$7.15B
$17.2M 0.36%
275,000
– –
2015 Q4
2 quarters
ALNY icon
21
CALL
Alnylam Pharmaceuticals
ALNY
$19.3B
$16.6M 0.34%
300,000
+150,000
+100% +$9.45M
2016 Q1
1 quarter
KITE
22
DELISTED
Kite Pharma
KITE
$16.2M 0.34%
325,000
-160,000
-33% -$7.86M
2014 Q3
7 quarters
TSLA icon
23
Tesla
TSLA
$1.37T
$15.9M 0.33%
+1,125,000
New +$17M
2016 Q2
0 quarters
AGIO icon
24
Agios Pharmaceuticals
AGIO
$1.65B
$15.7M 0.32%
375,000
+40,000
+12% +$1.98M
2013 Q3
11 quarters
JPM icon
25
CALL
JPMorgan Chase
JPM
$825B
$15.5M 0.32%
250,000
– –
2014 Q1
9 quarters

Similar funds

Artal Group's Q2 2016 Portfolio in Review

As of Q2 2016, Artal Group held 82 positions worth $4.84B, down 5.5% from $5.13B the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Artal Group's Q2 2016 filing shows 22 new, 15 increased, 12 reduced and 13 closed positions. Its largest new stake was Regeneron Pharmaceuticals: 50,000 shares worth $17.5M. The largest sale was Celgene, an estimated $37.2M.

By sector, the portfolio is most concentrated in Consumer Staples at 56% of assets, down from 58% a quarter earlier, followed by Healthcare and Miscellaneous.

  • Artal Group's largest Q2 2016 buy was Regeneron Pharmaceuticals: 50,000 shares worth $17.5M.
  • Artal Group added most to Alnylam Pharmaceuticals in Q2 2016, an estimated $6.93M increase.
  • Artal Group's biggest Q2 2016 reduction was Nektar Therapeutics, cutting an estimated $8.94M.
  • Artal Group fully exited Celgene in Q2 2016, selling an estimated $37.2M.
  • Artal Group's ten largest holdings make up 89% of its $4.84B portfolio in Q2 2016.
  • Artal Group opened 22 new positions and closed 13 in Q2 2016.
  • Artal Group's portfolio value fell 5.5% quarter-over-quarter to $4.84B.

Based on Artal Group's 13F filing for Q2 2016, filed 11 Aug 2016.